NASDAQ · VCYT
Veracyte, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VCYT: Nov 04, 2026
Veracyte, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0.28. The reported EPS for the same quarter last year was $0.38.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.28 | $0.31 | $0.26 | 2 |
| Dec 2026 | $0.31 | $0.32 | $0.31 | 2 |
| Mar 2027 | $0.31 | $0.37 | $0.26 | 2 |
| Jun 2027 | $0.38 | $0.42 | $0.33 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews- Zacks · Oct 29, 9:00 AM EDTTandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseTandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 28, 9:00 AM EDTVeracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 7:55 AM EDTHow to Find Strong Medical Stocks Slated for Positive Earnings SurprisesThe Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- RTTNews · Oct 23, 1:22 PM EDTVeracyte's Decipher Can Help Men Detect Prostate Cancer(RTTNews) – On Friday, Veracyte, Inc. (VCYT) announced new data showing that its Decipher Prostate Genomic Classifier can help identify men with very high-risk, nonmetastatic prostate cancer who may benefit from adding abiraterone to androgen deprivation therapy (ADT).
- Zacks · Oct 21, 11:10 AM EDTWill Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks · Oct 21, 7:55 AM EDTHow to Boost Your Portfolio with Top Medical Stocks Set to Beat EarningsWhy investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- Zacks · Oct 15, 8:28 AM EDTNatera Gains 118.1% in a Year: What's Driving the Rally?NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.
- Zacks · Oct 13, 10:03 AM EDTVeeva Systems' Basics Gains Traction With 175+ Emerging Biotech FirmsVEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug development processes.
- Zacks · Oct 9, 9:58 AM EDTANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YAngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
- Zacks · Oct 9, 9:43 AM EDTReasons to Hold Veeva Systems Stock in Your Portfolio for NowVEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
- Zacks · Oct 8, 12:22 PM EDTIs it the Right Time to Add Phibro Stock to Your Portfolio?PAHC's Animal Health gains from MFA, vaccine and mineral nutrition growth, but tariffs, costs and currency swings remain key risks to its outlook.
- Zacks · Oct 8, 12:18 PM EDTSmith+Nephew Launches CARTIHEAL Implant Across Key European MarketsSNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Veracyte, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.